[Systemic fibrinolysis following resuscitation or temporary electrostimulation].
Short-term systemic thrombolytic treatment with 1.5 million I.U. streptokinase or 1.8 million I.U. urokinase or APSAC was carried out in 13 patients with acute myocardial infarction (11 men, 2 women, mean age 61 [44-73] years) after cardiopulmonary resuscitation (n = 11) or transvenous electrostimulation (n = 2). In seven of the patients the infarct vessel was found to be patent after the course of thrombolytic therapy. No haemorrhagic complications occurred. Two patients died: one of a reinfarct at 3 months and the other suddenly at home at 6 months. These results show that short-term high dosage systemic thrombolytic treatment can be successfully performed in individual cases even after resuscitation or central venous catheterization, provided that any serious traumatic lesions or inadvertent arterial punctures have been avoided.
Jäger
D
D
Abteilung für Kardiologie und Angiologie, Klinikum der Ruhr-Universität Bochum.
Machraoui
A
A
Melz
F
F
Scholz-Jäger
A
A
Straub
H
H
Barmeyer
J
J
D000368:Aged; D016255:Anistreplase; D003131:Combined Modality Therapy; D004341:Drug Evaluation; D004554:Electric Countershock; D005260:Female; D005343:Fibrinolytic Agents / Q000627:therapeutic use*; D006336:Heart Massage; D006801:Humans; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000401:mortality / Q000628:therapy; D010958:Plasminogen / Q000627:therapeutic use*; D012008:Recurrence; D012151:Resuscitation; D013300:Streptokinase / Q000627:therapeutic use*; D015912:Thrombolytic Therapy; D014568:Urokinase-Type Plasminogen Activator / Q000627:therapeutic use*
D005343:Fibrinolytic Agents; D016255:Anistreplase; D010958:Plasminogen; D013300:Streptokinase; D014568:Urokinase-Type Plasminogen Activator
Systemische Fibrinolyse nach Reanimation oder passagerer Elektrostimulation.